Results 201 to 210 of about 5,937,095 (358)

Quality of inpatient test-and-treat malaria case-management in public and private hospitals in Kano State, Nigeria. [PDF]

Malar J
Getachew D, Ogbulafor N, Shekarau E, Musa B, Yusuf A, Haruna S, Oladosu OO, Oresanya O, Maxwell K, Zurovac D.   +9 more
europepmc   +1 more source

Assessment of patient safety culture in private and public hospitals in Peru

International Journal for Quality in Health Care, 2018
A. Arrieta, Gabriela L Suarez, Galed Hakim   +2 more
semanticscholar   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Sustainability in Ophthalmology: A Comparative Study of Knowledge, Attitudes, and Practices Among Surgeons and Nurses. [PDF]

Clin Ophthalmol
AlHilali S, AlBassam M, AlOmairini MI.
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers. [PDF]

Med Sci Monit
Güzel HG, Önder AH, İlhan Y, Balçık OY, Öztürk B.   +4 more
europepmc   +1 more source

Public Hospital Vs Private Hospital

European Proceedings of Social and Behavioural Sciences, 2017
openaire   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Redesigning healthcare facilities for sustainability: green hospital transformations and new infrastructure planning. [PDF]

BMC Health Serv Res
Maden Ş, Kerse G.
europepmc   +1 more source

Licensing of Private Mental Hospitals [PDF]

Public Health Reports (1896-1970), 1967
openaire   +2 more sources